NCT01741792View on ClinicalTrials.gov

Clinical Study With Blinatumomab in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)

PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

July 31, 2012

Primary Completion Date

July 31, 2014

Study Completion Date

September 30, 2015

Conditions

Diffuse Large B-cell Lymphoma

Interventions

DRUG

Blinatumomab

Administered by continuous intravenous infusion over 8 weeks in the first cycle and 4 weeks in the second cycle.

Trial Locations (6)

Unknown

Universitätsmedizin, Göttingen

Universitätsklinikum des Saarlandes, Homburg

Universitätsklinikum Schleswig Holstein, Kiel

Klinikum der Johannes-Gutenberg Universität, Mainz

Universitätsklinikum, Ulm

Universititätsklinikum, Würzburg

All Listed Sponsors

lead

Amgen Research (Munich) GmbH

INDUSTRY

NCT01741792 - Clinical Study With Blinatumomab in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL) | Biotech Hunter | Biotech Hunter